1-`(3r)-amino-4-(2-fluoro-phenyl)-butyl !-pyrrolidine-(2r)-carboxilic acid-benzyl amine derivatives and related compounds as dipeptidyl-peptidase IV (DPP-IV) inhibitors for the treatment of Type 2 diabetes mellitus

Details for Australian Patent Application No. 2005251461 (hide)

Owner Santhera Pharmaceuticals (Schweiz) AG

Inventors Matassa, Victor Giulio; Feurer, Achim; Cerezo-Galvez, Silvia; Thiemann, Meinolf; Nordhoff, Sonja; Edwards, Paul John; Lopez-Canet, Meritxell; Hill, Oliver

Agent Shelston IP

Pub. Number AU-A-2005251461

PCT Pub. Number WO2005/120494

Priority 04013510.5 08.06.04 EP

Filing date 8 June 2005

Wipo publication date 22 December 2005

International Classifications

A61K 31/401 (2006.01) - Proline

A61K 31/40 (2006.01) - having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil

A61K 31/472 (2006.01) - Non-condensed isoquinolines, e.g. papaverine

A61K 31/495 (2006.01) - having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine

C07D 207/08 (2006.01) Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom

C07D 207/09 (2006.01) Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom

C07D 207/16 (2006.01) Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom

C07D 217/14 (2006.01) Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems

C07D 217/16 (2006.01) Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems

C07D 217/26 (2006.01) Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems

C07D 241/04 (2006.01) Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings

Event Publications

14 December 2006 PCT application entered the National Phase

  PCT publication WO2005/120494 Priority application(s): WO2005/120494

24 September 2009 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(e). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005251462-Pharmaceutical compositions comprising polyethylene glycol having a molecular weight of less than 600 daltons

2005251459-Novel use of peptide compounds for treating amyotrophic lateral sclerosis